Eton Pharmaceuticals Acquires Exclusive U.S. Rights To PKU GOLIKE® From Relief Therapeutics, Expects To Be Accretive To Earnings In 2024

3/22/24 2:29:57 AM ET

$ETON

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ETON alert in real time by email

PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call point
Transaction is expected to be accretive to 2024 earnings
Estimated peak sales of more than $10 million annually
U.S. phenylketonuria ("PKU") medical formula market estimated to be $100 million annually

Get the next $ETON alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ETON

Date	Price Target	Rating	Analyst
9/4/2024	$9.00	Buy	H.C. Wainwright
5/6/2024	$8.00	Buy	Craig Hallum
10/14/2021	$10.00	Buy	B. Riley Securities

More analyst ratings

$ETON
Leadership Updates

Live Leadership Updates

Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer
DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of James Gruber as Chief Financial Officer, effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through the end of May to ensure a smooth transition. "We are pleased to welcome James to the Eton team. He brings a wealth of experience managing the finance and accounting activities for some of the most successful companies in the industry. We look forward to benefiting from his financial expertise as we
4/11/22 4:01:00 PM ET
$ETON
Biotechnology: Pharmaceutical Preparations
Health Care
Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director
LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the board of directors of the Company (the "Board"). He will hold office as an independent director until the next annual meeting of shareholders, or until his successor has been elected or appointed. Mr. Maier has also been appointed as a member of the Audit Committee and Corporate Governance and Nominating Committee and Chair of the Compensation Committee. Mr. Maier joins Small Pharma with over 30 years' ex
11/18/21 2:04:01 PM ET
$ETON
Biotechnology: Pharmaceutical Preparations
Health Care
Eton Pharmaceuticals Announces Appointment of Jenn Adams to its Board of Directors
DEER PARK, Ill., March 17, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has appointed Jenn Adams to its board of directors effective March 17, 2021. Ms. Adams brings extensive commercial, operational, and leadership experience in the pharmaceutical industry. “We are pleased to have Jenn join our board. Her experience growing pharmaceutical companies and leading sales organizations will be valuable to Eton as we continue to launch products and grow our commercial organization,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. Ms. Adam
3/17/21 4:05:00 PM ET
$ETON
Biotechnology: Pharmaceutical Preparations
Health Care

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted shareEntered into an asset purchase agreement to acquire Increlex® (mecasermin injection)Q3 2024 product sales increased 40% over Q3 2023, representing 15th straight quarter of sequential product sales growthProduced positive quarterly GAAP net income from product sales for first time in company historyGenerated cash from operations of $2.9 million in Q3 2024Granted additional patent for ET-400Management to hold conference call today at 4:30pm ET DEER PARK, Ill., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical c
11/12/24 4:01:00 PM ET
$ETON
Biotechnology: Pharmaceutical Preparations
Health Care
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial in (Audio Only) Toll-free: 888-596-4144 Non-toll free: 646-968-2525 Access Code: 1144771 Webcast: Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions fr
11/6/24 4:30:00 PM ET
$ETON
Biotechnology: Pharmaceutical Preparations
Health Care
SWK Holdings Provides Portfolio Update
Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results
10/17/24 4:15:00 PM ET
$BTCY
$DERM
$ELUT
$ETON
Medical/Dental Instruments
Health Care
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted shareEntered into an asset purchase agreement to acquire Increlex® (mecasermin injection)Q3 2024 product sales increased 40% over Q3 2023, representing 15th straight quarter of sequential product sales growthProduced positive quarterly GAAP net income from product sales for first time in company historyGenerated cash from operations of $2.9 million in Q3 2024Granted additional patent for ET-400Management to hold conference call today at 4:30pm ET DEER PARK, Ill., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical c
11/12/24 4:01:00 PM ET
$ETON
Biotechnology: Pharmaceutical Preparations
Health Care
Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)
- Product has patent protection through 2043 -- Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2025 - DEER PARK, Ill., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent Application No. 18/443,889, now U.S. Patent No. 12,133,914, for ET-400, a proprietary patented formulation of liquid hydrocortisone. The patent, which expires in 2043, covers a method of using hydrocortisone oral liquid formulat
11/7/24 7:00:00 AM ET
$ETON
Biotechnology: Pharmaceutical Preparations
Health Care
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial in (Audio Only) Toll-free: 888-596-4144 Non-toll free: 646-968-2525 Access Code: 1144771 Webcast: Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions fr
11/6/24 4:30:00 PM ET
$ETON
Biotechnology: Pharmaceutical Preparations
Health Care

Eton Pharmaceuticals Acquires Exclusive U.S. Rights To PKU GOLIKE® From Relief Therapeutics, Expects To Be Accretive To Earnings In 2024

Chat with this insight

Recent Analyst Ratings for $ETON

$ETON Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Opaleye Management Inc. bought $79,814 worth of shares (10,000 units at $7.98) (SEC Form 4)

Large owner Opaleye Management Inc. bought $434,137 worth of shares (62,070 units at $6.99) (SEC Form 4)

Large owner Opaleye Management Inc. bought $504,875 worth of shares (107,500 units at $4.70) (SEC Form 4)

$ETON SEC Filings

SEC Form 10-Q filed by Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

Eton Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$ETON Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Opaleye Management Inc. bought $79,814 worth of shares (10,000 units at $7.98) (SEC Form 4)

Large owner Opaleye Management Inc. bought $434,137 worth of shares (62,070 units at $6.99) (SEC Form 4)

SEC Form 4 filed by Chief Business Officer Krempa David

$ETON Leadership Updates

Live Leadership Updates

Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer

Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director

Eton Pharmaceuticals Announces Appointment of Jenn Adams to its Board of Directors

$ETON Market Insights

Live Market Insights

$ETON Financials

Live finance-specific insights

$ETON Press Releases

Fastest customizable press release news feed in the world

$ETON Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Eton Pharmaceuticals shares are trading higher after the company announced FDA acceptance of the New Drug Application for ET-400.

Eton Pharmaceuticals Received FDA Acceptance Of New Drug Application For ET-400

Eton Pharmaceuticals Q1 2024 GAAP EPS $(0.03) Beats $(0.07) Estimate, Sales $7.966M Miss $8.000M Estimate

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

SWK Holdings Provides Portfolio Update

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)

Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

H.C. Wainwright resumed coverage on Eton Pharmaceuticals with a new price target

Craig Hallum initiated coverage on Eton Pharmaceuticals with a new price target

B. Riley Securities resumed coverage on Eton Pharmaceuticals with a new price target

$ETON Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Eton Pharmaceuticals Inc.

SEC Form SC 13D/A filed by Eton Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Eton Pharmaceuticals Inc. (Amendment)

Recent Analyst Ratings for
$ETON

$ETON
Insider Purchases

$ETON
SEC Filings

$ETON
Insider Trading

$ETON
Leadership Updates

$ETON
Market Insights

$ETON
Financials

$ETON
Press Releases

$ETON
Analyst Ratings

$ETON
Large Ownership Changes